Key result
Immobilized prostacyclin prepared via conversion of immobilized prostaglandin F2 alpha showed dramatic antiplatelet effects on platelet aggregation and adhesion in vitro.
Why the study?
Does immobilized prostacyclin reduce platelet aggregation and adhesion in vitro?
Does immobilized prostacyclin reduce platelet aggregation and adhesion in vitro?
Immobilized prostacyclin can be successfully prepared and demonstrates significant antiplatelet effects in vitro without releasing prostacyclin from the substrate.
Answers are grounded in this paper and cite their sources.
Supports development of stable antiplatelet surfaces; leaves open translation to clinical devices pending in vivo validation.
Owing to the chemical instability of prostacyclin, the direct immobilization of this prostaglandin has not been successful. A new procedure is described for the preparation of immobilized prostacyclin based on the conversion of immobilized prostaglandin F2 alpha to immobilized prostaglandin I2-Materials thus prepared show dramatic antiplatelet effects with regard to platelet aggregation and platelet adhesion. Radioimmunoassays of plasmas used in in vitro platelet tests and of buffers used in prostacyclin leakage studies established that these effects are not due to the release of prostacyclin from the respective immobilization substrates.
No takes yet. Share an insight, caveat, or question.
Ebert et al. (1982) studied Platelet aggregation and adhesion. Immobilized prostacyclin was evaluated on Platelet aggregation and platelet adhesion. Immobilized prostacyclin prepared via conversion of immobilized prostaglandin F2 alpha showed dramatic antiplatelet effects on platelet aggregation and adhesion in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: